SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof. This patent covers the discovery of MANF and its composition of matter and complements the Company’s existing portfolio of issued patents and pending patent applications. The key claim allowed under the patent is as follows: A pharmaceutical composition comprising: (i) a substantially purified polypeptide comprising the sequence of SEQ ID NO: 2 (MANF); and (ii) a carrier that is pharmaceutically acceptable for administration to the central nervous system.
